SCHEDULE: abrdn Group Discloses 8.6% Stake in Immunic, Inc.
Beneficial Ownership Report
Aberdeen Group plc and its subsidiary abrdn Inc. have reported a beneficial ownership of 8.603% in Immunic, Inc.'s common stock.
Summary
- Aberdeen Group plc and its subsidiary abrdn Inc. collectively hold 8,243,941 shares of Immunic, Inc. common stock.
- This ownership represents 8.603% of the total class of securities.
- Both reporting entities share voting and dispositive power over all 8,243,941 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Immunic, Inc.
- Immunic, Inc.'s principal executive offices are located at 1200 Avenue of the Americas, Suite 200, New York, New York 10036.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It simply reports a significant stake.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing indicates a significant institutional investment in Immunic, Inc., a common occurrence in the biotechnology or pharmaceutical sector where specialized investment firms often take substantial positions in companies with promising pipelines or market potential. Such disclosures provide transparency regarding major shareholder interests.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.
- Company Management: Awareness of a large, passive institutional holder, though the filing states the stake is not for control purposes.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (beneficial ownership threshold met). |
| 07/31/2025 | Date the Schedule 13G statement was signed by reporting persons. |
Keywords
Immunic Inc, abrdn, Aberdeen Group plc, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Schedule 13G, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.